Active substance
Coagadex is indicated for the treatment and prophylaxis of bleeding episodes and for perioperative management in patients with hereditary factor X deficiency. Coagadex is indicated in all age groups.
| Product | Authorisation | Holder | Legal status |
|---|---|---|---|
| COAGADEX 250 IU POWDER AND SOLVENT FOR SOLUTION FOR INJECTION. | PLGB 08801/0059 | BIO PRODUCTS LABORATORY LIMITED | POM |
| COAGADEX 500 IU POWDER AND SOLVENT FOR SOLUTION FOR INJECTION | PLGB 08801/0060 | BIO PRODUCTS LABORATORY LIMITED | POM |
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), MHRA category lists of UK marketing authorisations (Open Government Licence v3.0), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.